Anti-cancer drugs - DNA targeting
Include alkylating agents, intercalating agents, and chain cutters.
Highly electrophilic species, looking for nucleophilic sites to attack, and forming covalent bonds to bases in DNAÂ
Prevent replication and transcriptionÂ
Toxic side effects (e.g. alkylation of proteins)Â
Bind in the major groove of DNA
Both types cross-link DNA by covalently bonding to nitrogen of base pairs.
Binding of nucleic acid bases results in miscoding and distortion.Â
Distortion of DNA prevents excision by HMG proteins â permanent damage.Â
Transcription and replication prevented, tumour growth slows.Â
Two electrophilic sites on an anticancer drug can cause interstrand and intrastrand cross-linking.
Preference for 1,2-GG or 1,2-GC linkage sites, with interstrand or intrastrand linkage, is dictated by drug chemical structureÂ
Other linkage adducts are possible. Eg 1,3-GCG, 1,2-GA.Â
Monofunctional adducts are also possibleÂ
Chlormethine (a nitrogen mustard)
 Chlormethine is highly reactive, toxic side effects.Â
Lead compound for many less toxic mustard derivatives.Â
Methyl (CH3 ) group has positive inductive effect â promotes loss of chloride â see mechanismÂ
Less toxic chlormethine analogues:
Melphalan: Â e- withdrawing ring lowers Nu strength of N, less reactive drug, less side effects, less toxic. Mimics PhAla, carried into cells by transport proteins.Â
Uracil mustard:Â Uracil ring is e-withdrawing, less reactive alkylating agent. Mimics a nucleic acid base, concentrates in fast growing cells.
Cyclophosphamide:Â Most commonly used alkylating agent, Non-toxic, orally active prodrug. Acrolein associated with toxicity.
Busulfan: Causes interstrand cross-linking. Sulphonate group withdraws electrons, adjacent carbon subject to Nu attack by DNA bases.Â
Dacarbazine â A diazine:Â Prodrug activated by oxidation in liver, decomposes to form methyldiazonium ion. Alkylates guanine groupsÂ
 Aminoacridines eg Proflavine
Antibiotics - Dactinomycin
Extra binding to sugar phosphate backbone by cyclic peptideÂ
Intercalates via minor groove of DNA double helixÂ
Prevents unwinding of DNA double helixÂ
Blocks transcription, blocks DNA-dependent RNA polymeraseÂ
Anthracyclines eg Doxorubicin (adriamycin)Â
 Extra binding to sugar phosphate backbone by NH3 Planar rings and Anthracyclines eg Doxorubicin (adriamycin)Â
Intercalates via major groove of DNA double helixÂ
 A topoisomerase poison - blocks action of topoisomerase II by stabilising DNA-enzyme complexÂ
Calicheamicin g1 I antitumour agentÂ
 Nucleophilic attack on trisulphide chain starts a rearrangement process.Â
This interacts with DNA to generate a DNA diradical, which reacts with oxygen, resulting in chain cutting.
Highly active head, neck, testicular cancer (Hodgkin lymphoma)Â
Single and double-strand cleavage of DNA with several reduced metal ions and O2 , Fe(II) highest in vivo activity.Â
bithiazole DNA binding domain (DBD) locks BLM into the minor groove,Â
carbohydrate domain (CHD) H-bonds BLM to sugar phosphate of DNAÂ
metal binding domain (MBD) bonds to Fe(II) Â Â
A reaction with hydrogen peroxide gives Fe(III) and hydroxyl radicals which abstract H atoms and cut the DNA chain.Â
Fe2+ + H2O2 Fe3+ + OH. + OHâ Fenton mechanismÂ
Lungs and skin have low levels of BLM hydrolase - higher sensitivity and toxicity. Pneumonitis occurs in about 10% of patients, progresses to pulmonary fibrosis. Over-expressed in malignant cells, resistance to bleomycin  Â
Summary of Anti-Tumour Specificity for DNAÂ
GG interstrand - N-mustards, nitrosoureas.Â
GG intrastrand - methanesulphonates.Â
GC-interstrand - nitrosoureas, triazines.Â
Minor groove intercalatorsÂ
GG interstrand â anthracyclines.Â
GC-interstrand â actinomycins, acridines.Â
Minor groove chain cuttersÂ
GC or GT intrastrand â bleomycinsÂ